Eyconis has dosed the first patients in Overture, a phase 1b/2a trial evaluating EYC-0305, an investigational long-acting anti-VEGF therapy, in treatment-naïve patients with neovascular age-related macular degeneration (AMD).

EYC-0305 is an anti-VEGF antibody fragment designed to provide sustained retinal drug exposure using TransCon technology licensed from Ascendis Pharma. Eyconis is developing the intravitreal therapy with the goal of achieving treatment intervals of 6 months or longer without an implant, device, or surgical procedure.

The open-label, multiple ascending dose study will evaluate the safety and tolerability of EYC-0305 across several dose levels. Participants are expected to receive a single intravitreal injection every 24 weeks without monthly loading doses. Pharmacokinetics, immunogenicity, disease activity, and visual outcomes will also be assessed.

The study is intended to inform subsequent clinical development, including whether EYC-0305 can provide disease control beyond 6 months. RP